Biomarin Pharmaceutical Inc (NASDAQ:BMRN) — Market Cap & Net Worth
Market Cap & Net Worth: Biomarin Pharmaceutical Inc (BMRN)
Biomarin Pharmaceutical Inc (NASDAQ:BMRN) has a market capitalization of $10.40 Billion ($10.40 Billion) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2174 globally and #786 in its home market, demonstrating a 0.15% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biomarin Pharmaceutical Inc's stock price $54.06 by its total outstanding shares 192323359 (192.32 Million). Analyse Biomarin Pharmaceutical Inc cash flow conversion to see how efficiently the company converts income to cash.
Biomarin Pharmaceutical Inc Market Cap History: 2015 to 2026
Biomarin Pharmaceutical Inc's market capitalization history from 2015 to 2026. Data shows change from $20.15 Billion to $10.40 Billion (-6.30% CAGR).
Index Memberships
Biomarin Pharmaceutical Inc is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$910.33 Billion | 1.14% | #19 of 30 |
|
Dow Jones Biotechnology
DJUSBT
|
$1.09 Trillion | 0.95% | #13 of 39 |
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.43% | #42 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.03% | #241 of 3165 |
|
S&P Midcap 400
MID
|
$3.36 Trillion | 0.43% | #108 of 401 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.62% | #29 of 263 |
Weight: Biomarin Pharmaceutical Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Biomarin Pharmaceutical Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biomarin Pharmaceutical Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.55x
Biomarin Pharmaceutical Inc's market cap is 3.55 times its annual revenue
Latest Price to Earnings (P/E) Ratio
32.76x
Biomarin Pharmaceutical Inc's market cap is 32.76 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $15.93 Billion | $1.12 Billion | -$630.21 Million | 14.27x | N/A |
| 2017 | $17.15 Billion | $1.31 Billion | -$117.04 Million | 13.05x | N/A |
| 2018 | $16.38 Billion | $1.49 Billion | -$77.21 Million | 10.98x | N/A |
| 2019 | $16.26 Billion | $1.70 Billion | -$23.85 Million | 9.54x | N/A |
| 2020 | $16.86 Billion | $1.86 Billion | $854.03 Million | 9.06x | 19.75x |
| 2021 | $16.99 Billion | $1.85 Billion | -$64.08 Million | 9.20x | N/A |
| 2022 | $19.90 Billion | $2.10 Billion | $141.56 Million | 9.50x | 140.60x |
| 2023 | $18.54 Billion | $2.42 Billion | $167.65 Million | 7.67x | 110.61x |
| 2024 | $12.64 Billion | $2.85 Billion | $426.86 Million | 4.43x | 29.61x |
| 2025 | $11.43 Billion | $3.22 Billion | $348.90 Million | 3.55x | 32.76x |
Competitor Companies of BMRN by Market Capitalization
Companies near Biomarin Pharmaceutical Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Biomarin Pharmaceutical Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Biomarin Pharmaceutical Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Biomarin Pharmaceutical Inc's market cap moved from $20.15 Billion to $ 10.40 Billion, with a yearly change of -6.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $10.40 Billion | -9.04% |
| 2025 | $11.43 Billion | -9.58% |
| 2024 | $12.64 Billion | -31.83% |
| 2023 | $18.54 Billion | -6.83% |
| 2022 | $19.90 Billion | +17.14% |
| 2021 | $16.99 Billion | +0.75% |
| 2020 | $16.86 Billion | +3.71% |
| 2019 | $16.26 Billion | -0.70% |
| 2018 | $16.38 Billion | -4.51% |
| 2017 | $17.15 Billion | +7.64% |
| 2016 | $15.93 Billion | -20.92% |
| 2015 | $20.15 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Biomarin Pharmaceutical Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.40 Billion USD |
| MoneyControl | $10.40 Billion USD |
| MarketWatch | $10.40 Billion USD |
| marketcap.company | $10.40 Billion USD |
| Reuters | $10.40 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biomarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV t… Read more